Jump to main content
Jump to site search

Issue 5, 2011
Previous Article Next Article

Group 9 metal-based inhibitors of β-amyloid (1–40) fibrillation as potential therapeutic agents for Alzheimer's disease

Author affiliations

Abstract

We report here the first application of Group 9 metal complexes (i.e.iridium(III) and rhodium(III)) as inhibitors of amyloid fibrillogenesis and as luminescent probes for Aβ1–40peptide. These complexes contained aromatic co-ligands to interact with the hydrophobic residues around the N-terminal domain of the Aβ1–40peptide, as well as solvato co-ligands to allow coordinative bond formation with histidine residues. We demonstrate that these complexes could inhibit Aβ1–40peptide aggregation in vitro, with potency superior to previous metal-based inhibitors reported. Furthermore, we have demonstrated the first example of luminescent detection of Aβ1–40peptides by transition metal complexes.

Graphical abstract: Group 9 metal-based inhibitors of β-amyloid (1–40) fibrillation as potential therapeutic agents for Alzheimer's disease

Back to tab navigation

Supplementary files

Article information


Submitted
20 Dec 2010
Accepted
02 Feb 2011
First published
25 Feb 2011

Chem. Sci., 2011,2, 917-921
Article type
Edge Article

Group 9 metal-based inhibitors of β-amyloid (1–40) fibrillation as potential therapeutic agents for Alzheimer's disease

B. Y. Man, H. Chan, C. Leung, D. S. Chan, L. Bai, Z. Jiang, H. Li and D. Ma, Chem. Sci., 2011, 2, 917
DOI: 10.1039/C0SC00636J

Social activity

Search articles by author

Spotlight

Advertisements